Equities research analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to post sales of $113.47 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for PTC Therapeutics’ earnings, with estimates ranging from $105.30 million to $116.97 million. PTC Therapeutics reported sales of $96.46 million during the same quarter last year, which indicates a positive year over year growth rate of 17.6%. The firm is scheduled to issue its next quarterly earnings report after the market closes on Thursday, February 25th.
On average, analysts expect that PTC Therapeutics will report full year sales of $375.07 million for the current year, with estimates ranging from $366.90 million to $378.87 million. For the next financial year, analysts expect that the firm will report sales of $462.52 million, with estimates ranging from $438.40 million to $516.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover PTC Therapeutics.
A number of equities research analysts have recently weighed in on PTCT shares. Raymond James lifted their price target on PTC Therapeutics from $63.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, December 16th. Smith Barney Citigroup raised PTC Therapeutics from a “neutral” rating to a “buy” rating in a report on Tuesday, January 5th. UBS Group initiated coverage on PTC Therapeutics in a report on Wednesday, October 28th. They set a “neutral” rating and a $55.00 target price on the stock. Royal Bank of Canada cut PTC Therapeutics from a “sector perform” rating to an “underperform” rating and set a $45.00 target price on the stock. in a report on Monday, November 30th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised PTC Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $67.00 to $85.00 in a report on Tuesday, January 5th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $63.08.
In other PTC Therapeutics news, CEO Stuart Walter Peltz sold 348,417 shares of PTC Therapeutics stock in a transaction that occurred on Monday, December 7th. The shares were sold at an average price of $61.00, for a total transaction of $21,253,437.00. Following the transaction, the chief executive officer now directly owns 248,877 shares in the company, valued at approximately $15,181,497. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Emily Luisa Hill sold 541 shares of PTC Therapeutics stock in a transaction that occurred on Monday, February 1st. The stock was sold at an average price of $56.96, for a total transaction of $30,815.36. Following the transaction, the chief financial officer now owns 23,306 shares in the company, valued at $1,327,509.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 679,554 shares of company stock worth $41,943,715. 7.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of PTCT. Avantax Advisory Services Inc. purchased a new position in PTC Therapeutics during the 3rd quarter worth approximately $438,000. Pacer Advisors Inc. purchased a new position in shares of PTC Therapeutics during the 3rd quarter valued at $100,000. Nisa Investment Advisors LLC grew its holdings in shares of PTC Therapeutics by 340.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,135 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 1,650 shares in the last quarter. Harbor Investment Advisory LLC grew its holdings in shares of PTC Therapeutics by 124.5% during the 3rd quarter. Harbor Investment Advisory LLC now owns 559 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 310 shares in the last quarter. Finally, Handelsinvest Investeringsforvaltning grew its holdings in shares of PTC Therapeutics by 20.0% during the 3rd quarter. Handelsinvest Investeringsforvaltning now owns 60,000 shares of the biopharmaceutical company’s stock valued at $2,805,000 after acquiring an additional 10,000 shares in the last quarter.
Shares of PTCT traded up $1.00 during mid-day trading on Thursday, reaching $58.40. 28,538 shares of the company’s stock traded hands, compared to its average volume of 530,135. The business’s 50-day moving average price is $63.02 and its 200-day moving average price is $57.00. The stock has a market capitalization of $3.98 billion, a P/E ratio of -8.21 and a beta of 1.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 4.83 and a current ratio of 4.90. PTC Therapeutics has a 12 month low of $30.79 and a 12 month high of $70.82.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
Featured Article: How can investors invest in the S&P/TSX Index?
Get a free copy of the Zacks research report on PTC Therapeutics (PTCT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.